Gross profit ToolGen 2017-2023

Published by Statista Research Department, May 14, 2024
In 2023, the gross profit of ToolGen amounted to around 935 billion South Korean won. This represents a significant increase from the previous year. Gross profits peaked in 2017 with around 2.9 trillion won. ToolGen is a South Korean biotech company based on CRISPR genome editing technology.

Gross profit of ToolGen from 2017 to 2023 (in million South Korean won)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2024

Region

Worldwide, South Korea

Survey time period

2017 to 2023

Special properties

consolidated from 2020 onwards

Supplementary notes

* Consolidated from 2020 onwards.

Figures have been rounded.

1,000 South Korean won equals 0.73 U.S. dollars or 0.68 euro as of May 2024.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Medical biotech industry "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Medical biotech industry

Global overview

7

U.S. and European landscape

6

Focus: U.S. companies

8

Research & development

6

Products

5

Funding/M&A/IPOs

6

Focus: RNA/mRNA

4

Further Content: You might find this interesting as well

Topics

CRISPR genome editingGlobal pharmaceutical industryBiotech drugsGenetically modified cropsAgriculture in the U.S.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.